SCHEMBL6992674

SCHEMBL6992674

CC1Oc2ccc(C=CC(N)=O)cc2NC1=S

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.41
PELI1 Q96FA3 1/20 0.35
HDAC1 Q13547 3/20 0.35
SMYD3 Q9H7B4 2/20 0.35
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAOB P27338 1/20 0.33
HPGD P15428 1/20 0.33
PARP1 P09874 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6996421 0.86 PARP1 (0.48) ALOX5SMYD3PARP1
SCHEMBL6996415 0.86 PARP1 (0.48) ALOX5SMYD3PARP1
SCHEMBL7710955 0.79 MAOA (0.40) ALOX5KDM4EALDH1A1MAOBPARP1
SCHEMBL6994006 0.77 ALOX5 (0.36) ALOX5KDM4EPARP1
SCHEMBL6992815 0.76 PARP1 (0.48) ALOX5PELI1SMYD3MAOBPARP1
SCHEMBL6992811 0.76 PARP1 (0.48) ALOX5PELI1SMYD3MAOBPARP1
SCHEMBL8119255 0.75 PARP1 (0.43) ALOX5SMYD3PARP1
SCHEMBL531954 0.74 ALOX5 (0.55) ALOX5HDAC1SMYD3KDM4EALDH1A1
SCHEMBL531955 0.74 ALOX5 (0.55) ALOX5HDAC1SMYD3KDM4EALDH1A1
SCHEMBL7000474 0.72 PARP1 (0.37) SMYD3KDM4EALDH1A1PARP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed